EUVIMED · CrossrefZeitschrift
Japanese Journal of Clinical Oncology
ISSN 1465-3621 · Oxford University Press (OUP)
Neueste Artikel
Nomogram of conditional survival probability in oldest old patients with colorectal cancer after surgical resection: a multicenter retrospective cohort study
A perioperative immunonutritional nomogram for survival prediction beyond tumor-node-metastasis classification in ampullary adenocarcinoma
A clinical risk model predicts over 300 ILD-free days in urological cancer patients on immune checkpoint inhibitors
Influence of pathologic fractures on oncologic outcomes in extremity Ewing sarcoma: a single-institution retrospective study
End-of-life cancer care quality in rural areas of Japan: an exploratory bereaved family survey
Short-term efficacy and safety of enfortumab vedotin plus pembrolizumab as a first-line treatment for advanced urothelial carcinoma regardless of cisplatin eligibility
Dose intensity and clinical outcomes across age groups in high-grade osteosarcoma treated with methotrexate, adriamycin, and cisplatin therapy
A multicenter randomized phase III trial to evaluate the value of omission of elective neck dissection for T3–T4aN0 laryngeal cancer: JCOG2407 (JALNECK)
PCU-to-home transition sequences and final place of death in advanced cancer: a prospective Japanese cohort study of a regional electronic communication platform
A single-arm phase III trial evaluating the non-inferiority of less-intensive surveillance for early gastric cancer: JCOG2504 (less-surveillance EGC)
Prognostic significance of non–muscle-invasive late recurrence after intravesical bacillus Calmette–Guérin therapy in bladder cancer: a multicenter, retrospective real-world study (the Japan Urological Oncology Group)
Prognostic impact of regional lymph node metastasis at castration-resistant prostate cancer diagnosis on survival after radium-223 treatment
Impact of severe postoperative complications on oncologic outcomes after curative resection for stage I–III colorectal cancer: a multicenter study
Extramedullary multiple myeloma simulating lymphoproliferative disease on multimodality imaging
Atezolizumab vs durvalumab for extensive-stage small cell lung cancer in Japan: a real-world comparative analysis of costs and clinical outcomes
Clinical significance of spread through air spaces according to EGFR mutation status in lung adenocarcinoma
De-escalation of perioperative systemic therapy for early breast cancer
Endoscopy-assisted precise radical hysterectomy and perioperative chemotherapy for locally advanced cervical cancer: feasibility and clinical outcomes compared with radiotherapy
A Bayesian reanalysis of the THOR trial cohort 1 using reconstructed individual patient data: interval-specific effects and clinically interpretable estimands under non-proportional hazards
Letermovir coadministration and tacrolimus concentration-to-dose ratios before and after intravenous-to-oral conversion in allogeneic hematopoietic stem cell transplant recipients receiving isavuconazole
Conversion surgery for gastric cancer: current status and future perspectives
Crude incidence rates of Tier 2 rare cancers within the RARECAREnet DIGESTIVE RARE family in Japan and the United States (2016–2020)
Fertility-sparing surgery for early-stage epithelial ovarian cancer: evolving criteria for patient selection
Separating advance care planning from end-of-life care in Japan: a reframing for an era of improving cancer survival
Azole-mediated CYP3A inhibition and persistent gastrointestinal GVHD increase tacrolimus oral bioavailability after allo-HSCT
Lenvatinib dose intensity and tumor response in renal cell carcinoma: considering tumor burden and nephrectomy timing
Lenvatinib dose intensity and tumor response in renal cell carcinoma: considering tumor burden and nephrectomy timing
Northward shift in cancer mortality inequality across Japanese prefectures, 1995–2023, a nationwide ecological study
Metastasis-directed radiotherapy for oligoprogressive castration-resistant prostate cancer: clinical outcomes and factors associated with durable disease control
Comparison of first-line treatment strategies for metastatic hormone-sensitive prostate cancer in Japanese clinical practice since 2020: a multicenter registry study
Jahrgänge
2026 · 1972025 · 2212024 · 1942023 · 1852022 · 2122021 · 2842020 · 2132019 · 2042018 · 1922017 · 2082016 · 2012015 · 2312014 · 2352013 · 2242012 · 2212011 · 2622010 · 2402009 · 1242008 · 1882007 · 1702006 · 1722005 · 1662004 · 1472003 · 1082002 · 1182001 · 1272000 · 1281999 · 1721998 · 2041997 · 1001996 · 1051995 · 611994 · 701993 · 661992 · 911991 · 851990 · 671989 · 741988 · 511987 · 49
EUVIMED